Literature DB >> 29071483

[S1 guidelines on diagnostics and treatment of ANCA-associated vasculitis].

Jan H Schirmer1, Frank Moosig2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29071483     DOI： 10.1007/s00393-017-0393-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  7 in total

1.  BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.

Authors:  Eleana Ntatsaki; David Carruthers; Kuntal Chakravarty; David D'Cruz; Lorraine Harper; David Jayne; Raashid Luqmani; John Mills; Janice Mooney; Michael Venning; Richard A Watts
Journal:  Rheumatology (Oxford)       Date:  2014-04-11       Impact factor: 7.580

2.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Authors:  Alexandre Karras; Christian Pagnoux; Marion Haubitz; Kirsten de Groot; Xavier Puechal; Jan Willem Cohen Tervaert; Mårten Segelmark; Loic Guillevin; David Jayne
Journal:  Ann Rheum Dis       Date:  2017-05-25       Impact factor: 19.103

3.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

Review 4.  Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.

Authors:  Xavier Bossuyt; Jan-Willem Cohen Tervaert; Yoshihiro Arimura; Daniel Blockmans; Luis Felipe Flores-Suárez; Loïc Guillevin; Bernhard Hellmich; David Jayne; J Charles Jennette; Cees G M Kallenberg; Sergey Moiseev; Pavel Novikov; Antonella Radice; Judith Anne Savige; Renato Alberto Sinico; Ulrich Specks; Pieter van Paassen; Ming-Hui Zhao; Niels Rasmussen; Jan Damoiseaux; Elena Csernok
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

5.  Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.

Authors:  Seerapani Gopaluni; Rona M Smith; Michelle Lewin; Carol A McAlear; Kim Mynard; Rachel B Jones; Ulrich Specks; Peter A Merkel; David R W Jayne
Journal:  Trials       Date:  2017-03-07       Impact factor: 2.279

6.  Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial.

Authors:  Michael Walsh; Peter A Merkel; Chen Au Peh; Wladimir Szpirt; Loïc Guillevin; Charles D Pusey; Janak De Zoysa; Natalie Ives; William F Clark; Karen Quillen; Jeffrey L Winters; Keith Wheatley; David Jayne
Journal:  Trials       Date:  2013-03-14       Impact factor: 2.279

7.  EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Authors:  M Yates; R A Watts; I M Bajema; M C Cid; B Crestani; T Hauser; B Hellmich; J U Holle; M Laudien; M A Little; R A Luqmani; A Mahr; P A Merkel; J Mills; J Mooney; M Segelmark; V Tesar; K Westman; A Vaglio; N Yalçındağ; D R Jayne; C Mukhtyar
Journal:  Ann Rheum Dis       Date:  2016-06-23       Impact factor: 27.973
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.